Empagliflozin Ammeliorates High Glucose Induced-Cardiac Dysfuntion in Human iPSC-Derived Cardiomyocytes

Empagliflozin, a sodium-glucose co-transporter (SGLT) inhibitor, reduces heart failure and sudden cardiac death but the underlying mechanisms remain elusive. In cardiomyocytes, SGLT1 and SGLT2 expression is upregulated in diabetes mellitus, heart failure, and myocardial infarction. We hypothesise th...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Sci Rep
Asıl Yazarlar: Ng, Kwong-Man, Lau, Yee-Man, Dhandhania, Vidhu, Cai, Zhu-Jun, Lee, Yee-Ki, Lai, Wing-Hon, Tse, Hung-Fat, Siu, Chung-Wah
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group UK 2018
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6173708/
https://ncbi.nlm.nih.gov/pubmed/30291295
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-018-33293-2
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller